LEXOTAN

This brand name is authorized in Australia, Brazil, Ecuador, Hong Kong SAR China, Ireland, Japan, Malta, Mexico, Poland, Singapore, South Africa.

Active ingredients

The drug LEXOTAN contains one active pharmaceutical ingredient (API):

1	Bromazepam UNII X015L14V0O - BROMAZEPAM
	Bromazepam is a pyridylbenzodiazepine compound with anxiolytic properties.
	Read more about Bromazepam

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LEXOTAN Tablet	MPI, EU: SmPC	Health Products Regulatory Authority (IE)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N05BA08	Bromazepam	N Nervous system → N05 Psycholeptics → N05B Anxiolytics → N05BA Benzodiazepine derivatives
Discover more medicines within N05BA08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	4150K, 4151L
BR	Câmara de Regulação do Mercado de Medicamentos	529203001117312, 529203003111311, 544220070001217, 544220070001317
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	29498-1-11-10
HK	Department of Health Drug Office	03341, 03365
IE	Health Products Regulatory Authority	31115, 31129
JP	医薬品医療機器総合機構	1124020C1045, 1124020F1025, 1124020F2030, 1124020F4032
MT	Medicines Authority	AA729/25702
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	80663
PL	Rejestru Produktów Leczniczych	100037490, 100182475, 100183730, 100246873, 100293944, 100310460, 100324656, 100346221, 100346391, 100398821, 100399281, 100407632, 100408531, 100422940, 100433204, 100452902, 100454672, 100457054, 100463099
SG	Health Sciences Authority	00382P, 00385P
ZA	Health Products Regulatory Authority	G/2.6/86, G/2.6/87